Genmab A/S (LON:0MGB)
2,011.50
-4.89 (-0.24%)
At close: Dec 18, 2025
Genmab Revenue
Genmab had revenue of $1.02B USD in the quarter ending September 30, 2025, with 25.25% growth. This brings the company's revenue in the last twelve months to $3.47B, up 18.01% year-over-year. In the year 2024, Genmab had annual revenue of $3.00B with 23.13% growth.
Revenue (ttm)
$3.47B
Revenue Growth
+18.01%
P/S Ratio
5.20
Revenue / Employee
$1.29M
Employees
2,682
Market Cap
14.87B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00B | 564.17M | 23.13% |
| Dec 31, 2023 | 2.44B | 351.45M | 16.83% |
| Dec 31, 2022 | 2.09B | 800.56M | 62.19% |
| Dec 31, 2021 | 1.29B | -372.56M | -22.45% |
| Dec 31, 2020 | 1.66B | 854.43M | 106.10% |
| Dec 31, 2019 | 805.32M | 340.75M | 73.35% |
| Dec 31, 2018 | 464.57M | 83.37M | 21.87% |
| Dec 31, 2017 | 381.20M | -144.81M | -27.53% |
| Dec 31, 2016 | 526.01M | 195.32M | 59.07% |
| Dec 31, 2015 | 330.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |
Genmab News
- 8 days ago - Genmab Meets Conditions For $97/shr Merus Tender Offer - Nasdaq
- 9 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 9 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewsWire
- 9 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow - Seeking Alpha
- 9 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript - Seeking Alpha
- 10 days ago - Genmab to Hold 2025 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 12 days ago - Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial - GuruFocus
- 12 days ago - Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - Business Wire